---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033874"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:51:33.183508+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q2 net loss narrows to $17.7M; cash $295.7M; CFT1946 ESMO data Sept 14

## Summary
- Revenue $12.0M vs $2.7M YoY, driven by $8M Biogen milestone.
- Net loss $17.7M ($0.26 per share) vs $35.9M ($0.73) in Q2 2023.
- Cash $295.7M; expects runway into 2027.
- CFT1946 Phase 1 monotherapy data to be presented at ESMO Congress 2024 on Sept 14.
- Cemsidomide Phase 1 data in MM and NHL on track for Q4 2024.

## SEC filing metadata
- accession: 0001628280-24-033874
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/0001628280-24-033874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024033874/cccc-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033874
- JSON: https://secwatch.observer/filing/0001628280-24-033874.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.